Pfizer signs $340 million licensing pact with GlycoMimetics

10/11/2011 | American City Business Journals

GlycoMimetics entered a global licensing agreement with Pfizer for GMI-1070, an experimental treatment for vaso-occlusive crisis in patients with sickle cell disease. The deal calls for GlycoMimetics to complete the drug's Phase II study, then turn over further development and commercialization to Pfizer. GlycoMimetics is entitled to upfront, milestone and royalty payments worth as much as $340 million.

View Full Article in:

American City Business Journals

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Sr Manager, Business Conduct
Gilead Sciences
Foster City, CA
Chief Executive Officer
UCare Minnesota
Minneapolis, MN